Bank of India Large & Mid Cap Fund
The scheme aims at income and long-term capital appreciation by investing through a diversified portfolio of predominantly large cap and mid cap equity and equity-related securities including equity derivatives.
Growthvine rating: 2/5 — ranked #31 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹87.05 (as of 2026-10-22) |
|---|
| AUM | ₹529 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nitin Gosar |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 9.87% |
|---|
| Sharpe ratio | 0.38 |
|---|
| Standard deviation | 16.18% |
|---|
| Max drawdown | −39.51% |
|---|
| Alpha | 2.25 |
|---|
| Beta | 1.01 |
|---|
Over 5 years, captured 95.5% of NIFTY LargeMidcap 250's upside and 99.7% of its downside.
Market cap allocation
| Large cap | 45.8% |
|---|
| Mid cap | 38.0% |
|---|
| Small cap | 16.1% |
|---|
Concentration
| Top 5 holdings | 24.6% |
|---|
| Top 10 holdings | 39.2% |
|---|
| Total holdings | 48 |
|---|
| Index overlap | 26.3% |
|---|
| Active share | 73.7% |
|---|
Top holdings
- HDFC Bank Ltd. — 8.1%
- Reliance Industries Ltd — 6.1%
- TREPS — 5.8%
- Kotak Mahindra Bank Ltd. — 3.8%
- Larsen & Toubro Limited — 3.4%
- State Bank Of India — 3.2%
- Dixon Technologies (India) Limited — 3.0%
- Aurobindo Pharma Ltd. — 3.0%
- PETRONET LNG LTD. — 3.0%
- FSN E-Commerce Ventures Limited — 2.8%
Top sectors
- Banking & Financial — 20.8%
- Pharma & Biotech — 12.2%
- Retail — 7.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −5.4% | Q2 | #18 of 38 |
| 2025 | 6.8% | Q2 | #12 of 34 |
| 2024 | 16.6% | Q4 (Bottom) | #23 of 29 |
| 2023 | 29.3% | Q3 | #16 of 28 |
| 2022 | 1.9% | Q2 | #14 of 28 |